Product Description

With rich market knowledge as well as experience we have been able to emerge as a reliable organization engaged in offering Blincyto Blinatumomab. The drug is highly effective for the treatment of refractory B-cell precursor acute lymphoblastic leukemia. This drug is procured from the trusted and reliable vendors of the market by our agents. Before packing in air tight materials, Blincyto Blinatumomab is tested on safety and purity parameters.

Features:

• Administered as intravenous infusion
• Low indication of side effects
  
• Longer shelf life